| The potential and controversy of targeting STAT family members in cancer Y Verhoeven, S Tilborghs, J Jacobs, J De Waele, D Quatannens, ... Seminars in cancer biology 60, 41-56, 2020 | 328 | 2020 |
| Cold atmospheric plasma-treated PBS eliminates immunosuppressive pancreatic stellate cells and induces immunogenic cell death of pancreatic cancer cells J Van Loenhout, T Flieswasser, L Freire Boullosa, J De Waele, ... Cancers 11 (10), 1597, 2019 | 107 | 2019 |
| The influence of cell type and culture medium on determining cancer selectivity of cold atmospheric plasma treatment E Biscop, A Lin, W Van Boxem, J Van Loenhout, J De Backer, C Deben, ... Cancers 11 (9), 1287, 2019 | 104 | 2019 |
| TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value C Deben, V Deschoolmeester, F Lardon, C Rolfo, P Pauwels Critical reviews in oncology/hematology 99, 63-73, 2016 | 91 | 2016 |
| Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer LF Boullosa, J Van Loenhout, T Flieswasser, J De Waele, C Hermans, ... Redox biology 42, 101949, 2021 | 88 | 2021 |
| APR-246 (PRIMA-1MET) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines C Deben, F Lardon, A Wouters, KO de Beeck, J Van den Bossche, ... Cancer letters 375 (2), 313-322, 2016 | 84* | 2016 |
| The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer C Deben, A Wouters, KO de Beeck, J van Den Bossche, J Jacobs, ... Oncotarget 6 (26), 22666, 2015 | 79 | 2015 |
| Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer J Jacobs, K Zwaenepoel, C Rolfo, J Van den Bossche, C Deben, ... Oncotarget 6 (15), 13462, 2015 | 76 | 2015 |
| Oxidative stress-inducing anticancer therapies: taking a closer look at their immunomodulating effects J Van Loenhout, M Peeters, A Bogaerts, E Smits, C Deben Antioxidants 9 (12), 1188, 2020 | 73 | 2020 |
| Hypoxia-induced cisplatin resistance in non-small cell lung cancer cells is mediated by HIF-1α and mutant p53 and can be overcome by induction of oxidative stress C Deben, V Deschoolmeester, J De Waele, J Jacobs, J Van den Bossche, ... Cancers 10 (4), 126, 2018 | 59 | 2018 |
| Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation J Jacobs, V Deschoolmeester, K Zwaenepoel, T Flieswasser, C Deben, ... Oncoimmunology 7 (7), e1440167, 2018 | 55 | 2018 |
| Cancer-associated fibroblasts as a common orchestrator of therapy resistance in lung and pancreatic cancer A Domen, D Quatannens, S Zanivan, C Deben, J Van Audenaerde, ... Cancers 13 (5), 987, 2021 | 54 | 2021 |
| Auranofin and cold atmospheric plasma synergize to trigger distinct cell death mechanisms and immunogenic responses in glioblastoma J Van Loenhout, L Freire Boullosa, D Quatannens, J De Waele, C Merlin, ... Cells 10 (11), 2936, 2021 | 50 | 2021 |
| Poly (I: C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade J De Waele, E Marcq, JRM Van Audenaerde, J Van Loenhout, C Deben, ... Oncoimmunology 7 (3), e1407899, 2018 | 49 | 2018 |
| Cellular senescence in cancer: clinical detection and prognostic implications A Domen, C Deben, J Verswyvel, T Flieswasser, H Prenen, M Peeters, ... Journal of Experimental & Clinical Cancer Research 41 (1), 360, 2022 | 48 | 2022 |
| Expression analysis on archival material revisited: isolation and quantification of RNA extracted from FFPE samples C Deben, K Zwaenepoel, C Boeckx, A Wouters, P Pauwels, M Peeters, ... Diagnostic Molecular Pathology 22 (1), 59-64, 2013 | 36 | 2013 |
| Deep sequencing of the TP53 gene reveals a potential risk allele for non–small cell lung cancer and supports the negative prognostic value of TP53 variants C Deben, J Van den Bossche, N Van Der Steen, F Lardon, A Wouters, ... Tumor Biology 39 (2), 1010428317694327, 2017 | 35 | 2017 |
| OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening C Deben, EC De La Hoz, ML Compte, P Van Schil, JMH Hendriks, ... Cellular Oncology 46 (2), 299-314, 2023 | 33 | 2023 |
| Urine biomarkers in cancer detection: A systematic review of preanalytical parameters and applied methods S Jordaens, K Zwaenepoel, W Tjalma, C Deben, K Beyers, ... International Journal of Cancer 152 (10), 2186-2205, 2023 | 31 | 2023 |
| Mass spectrometry imaging reveals neutrophil defensins as additional biomarkers for anti-PD-(L) 1 immunotherapy response in NSCLC patients E Berghmans, J Jacobs, C Deben, C Hermans, G Broeckx, E Smits, ... Cancers 12 (4), 863, 2020 | 26 | 2020 |
